Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 3/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.62 |
| ▸ | MEN1 | O00255 | 4/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17782448 | 0.83 | NR4A2 (0.70) | NR4A2KMT2AMEN1MAPTLMNA | |
| SCHEMBL4137522 | 0.83 | NR4A2 (0.66) | NR4A2KMT2AMEN1MAPTLMNA | |
| SCHEMBL2000654 | 0.81 | NR4A2 (0.63) | NR4A2KMT2AMEN1MAPTLMNA | |
| SCHEMBL6298233 | 0.80 | NR4A2 (0.61) | NR4A2KMT2AMEN1MAPTLMNA | |
| SCHEMBL408819 | 0.80 | NR4A2 (1.00) | NR4A2KMT2AMEN1MAPTLMNA | |
| SCHEMBL13209353 | 0.77 | NR4A2 (0.65) | NR4A2KMT2AMEN1MAPTLMNA | |
| SCHEMBL408830 | 0.76 | HDAC1 (0.49) | MAPTLMNAPOLBGAASMN1; SMN2 | |
| SCHEMBL4239994 | 0.76 | NR4A2 (0.60) | NR4A2KMT2AMEN1MAPTLMNA | |
| SCHEMBL4243232 | 0.76 | NR4A2 (0.56) | NR4A2KMT2AMEN1MAPTLMNA | |
| SCHEMBL15558170 | 0.76 | NR4A2 (0.69) | NR4A2KMT2AMEN1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065196-A1 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-15 | — | — | US | disclosed |
| WO-2008011130-A2 | AMIDE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065196-A1 | AMIDE COMPOUNDS | DGAT2, DGAT1, DLAT | NR4A2 1041/4885KMT2A 667/4885MEN1 4411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.